选择规格
变更视图
关于此项目
经验公式(希尔记法):
C27H29NO11 · xHCl
化学文摘社编号:
分子量:
543.52 (free base basis)
UNSPSC Code:
12352200
MDL number:
eCl@ss:
32150312
Quality Segment
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
orange-red
solubility
water: 1 mg/mL
shipped in
ambient
storage temp.
2-8°C
InChI
1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1
InChI key
MWWSFMDVAYGXBV-FGBSZODSSA-N
General description
A cell-permeable, antitumor antibiotic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.
This product has been discontinued.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Antitumor antibiotic
Antitumor antibiotic
Product does not compete with ATP.
Reversible: no
Preparation Note
Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Luck, H.J., et al. 1996. Semin. Oncol.23, 33.
Sandri, M.I., et al. 1996. Br. J. Cancer73, 1518.
Boddy, A.V., et al. 1995. Eur. J. Cancer31A, 69.
Pouna, P., et al. 1995. Cancer. Chemother. Pharmacol.35, 257.
Sandri, M.I., et al. 1996. Br. J. Cancer73, 1518.
Boddy, A.V., et al. 1995. Eur. J. Cancer31A, 69.
Pouna, P., et al. 1995. Cancer. Chemother. Pharmacol.35, 257.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful & Carcinogenic / Teratogenic (E)
警示词
Danger
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点 (F)
Not applicable
闪点 (°C)
Not applicable

